Background: Cervical lesions are known to occur at high frequency as a complication of rheumatoid arthritis (RA). Treatment with biological agents are more clinically effective than the DMARDs that were in use previously, in particular, with their efficacy in suppressing joint destruction having been emphasized. We reported the efficacy of infliximab, anti-tumor necrosis factor antibodies for suppressing the radiographic progression of RA cervical lesions at ACR2009, EULAR2010, 11, 12, 13, 14 and 16 . However there is still few studies of efficacy of against RA cervical lesions of Tocilizumab (TCZ), anti-interleukin 6 receptor antibody. Objectives: To evaluate the efficacy of TCZ for suppressing the radiographic progression of RA cervical lesions comparison with MTX for 2 years. Methods: We used TCZ or MTX for treating Japanese patients with active RA who fulfilled the ACR criteria in 1987. The final study cohort of each 38 and 71 patients received continuous TCZ and MTX treatment for at least 2 years. For evaluation of cervical lesions, the atlanto-dental interval (ADI), the space available for the spinal cord (SAC), and the Ranawat value were measured by plain lateral radiographs in the flexion position, at initiation and Year 1,2. Results: In the patients receiving TCZ (n=38) and MTX (n=71), the number of female were each 28 (72%) and 51 (72%) cases (p=0.999). The mean age was 57.3±12.4 and 63.3±10.9 years old (p=0.011); disease duration was 7.0±7.3 and 8.8±9.7 years (p=0.929) and the mean dose of MTX was 9.0±3.4 and 8.3±2.9 mg/w (p=0.335). Clinical findings related to RA were as follows; CRP 3.8±3.1 and 1.5±2.1 mg/dl (p<0.001); ESR 52.7±25.3 and 30.0±20.8mm/h (p<0.001); MMP3 400±300 and 213±356ng/ml (p<0.001); the number of RF-positive 30 (79%) and 58 (82%) Background: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by fluctuating disease activity in which adverse long-term outcomes remain a major challenge. In the face of extreme individual unpredictability of the disease course over time, four different patterns can be defined, as elsewhere described [1], using SLEDAI-2K (Systemic Lupus Erythematosus Disease Activity Index-2K) excluding serology in order to focus on clinical activity. The patterns are clinical quiescent disease (CQD), chronic active disease (CAD), relapsing-remitting disease (RRD) and minimal disease activity (MDA). Objectives: The aim of our study was to assess the association between different disease activity patterns and damage accrual in SLE patients. Methods: Patients with SLE registered at our Lupus Clinic at the Rheumatology Unit, between 1 January 2013 and 1 October 2016, were included. Demographic and clinical variables included age, gender, age at SLE onset, major organ involvement. SDI (Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index) was categorized as absent (SDI=0) or present (SDI ≥1), Disease activity patterns (CQD, MDA, RRD, CAD) were retrospectively assessed. Drugs used in the treatment of SLE, including hydroxychloroquine, cumulative dose of glucocorticoid (prednisone equivalent >10 g) and other immunosuppressive drugs, were also collected. Multivariate logistic regression analyses were performed to identify disease patterns associated with damage accrual. Results are presented as odds ratio (OR) and 95% confidence intervals (CI). Results: A total of 473 Caucasian patients were observed, mainly female (89.4% F, 10.6% M), mean age 52.6 years (± 14.9 SD). In our cohort, the disease activity pattern distribution was as follows: 65.4% CQD (290 pts), 21.5% RRD (91 pts), 6.1% MDA (28 pts) and CAD in 19.1% of the cases (64 pts). Damage was significantly more frequent in CAD subset (81.2%, 52/64 pts) versus 54.5% in CQD (158/290 pts), 50% in MDA (14/28 pts) and 58.2% in RRD (53/91 pts). Compared to a CQD course, CAD pattern was independently associated with overall damage after controlling for factors including gender, disease duration, cumulative glucocorticoid dosage, major individual organ involvement (neuropsychiatric and renal), positive antiphospholipid antibody profile, exposures to cyclophosphamide and hydroxychloroquine (Table 1) .
Conclusions:
Our results demonstrated that a clinically and persistent CAD triples the risk of damage compared to milder or relapsing courses, while hydroxychloroquine appeared to have a "protective" effect. Identifying the prevailing pattern of disease activity in every patient can be translated into a more effective personalized preventing strategy to reduce damage accrual and improve outcomes. Rheumatology, Hospital, Basel, Switzerland; 5 Rheumatology, Hospital, Nancy, France; 6 Rheumatology, Hospital, Copenhagen, Denmark; 7 Rheumatology, Hospital, Turin, Italy; 8 Rheumatology, Hospital, Madrid, Spain; 9 Rehabilitation, Hospital, Mexico City, Mexico; 10 Rheumatology, Hospital, Siena, Italy;  11 Rheumatology, Hospital, Bruneck, Austria; 12 Rheumatology & Rehabilitation Department, Hospital, Zagazig, Egypt;  13 Rheumatology, Hospital, Ljubljana, Slovenia; 14 Rheumatology, Hospital, Esbjerg, Denmark; 15 Rheumatology, Hospital, Cairo, Egypt;  16 Rheumatology, Hospital, Barcelona, Spain; 17 Rheumatology, Hospital, Rochester; 18 Rheumatology, Hospital, Whitefish, United States; 19 Rheumatology, Hospital, Freiburg, Germany; 20 Rheumatology, Hospital, Prague, Czech Republic; 21 Rheumatology, Hospital, Bergen, Norway; 22 Rheumatology, Hospital, France; 23 Rheumatology, Hospital, MC Groep Hospitals, Lelystad, Netherlands Background: Ultrasonography (US) of salivary glands (USSG) may support diagnosis and evaluation of disease activity in primary Sjögren's syndrome pSS. In order to extent the use of USSG in daily practice, consensus definitions of normal and abnormal USSG findings are needed. Objectives: To obtain consensual definitions of normal and abnormal USSG findings using a Delphi process. Methods: Twenty-seven experts participated in the Delphi process. A Likert scale from 1-5 was used in which 1 indicated complete disagreement and 5 complete agreement. Three core items were proposed: 1. Consensus of assessment of SG (parotid gland (PG), submandibular glands (SMG), sublingual glands SLG)). 2. Consensus for elementary lesions of PG, SMG, and SLG changes in PSS patients. 3. Consensus on grading of PG, SM, and SLG in pSS. Results: The consensus of definitions between experts was reached after three rounds.The results (table 1) showed agreement with more than 75% of agreement in normal and abnormal definitions in SG and concluded to not evaluate SLG in pSS patients as well as to score pSS SG patients with at least two abnormal glands out of 4 (2 PG and 2 SMG) with a scoring system >2 for each abnormal gland.
We developed a consensual US definition of normal and abnormal USGS findings through a Delphi exercise process. This finding will be used as a basis to further proceed with the validation of USGS for clinical application. Disclosure of Interest: None declared DOI: 10.1136/annrheumdis-2017-eular.4976 
